Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors

Research output: Contribution to journalReview articleAcademicpeer-review

1 Citation (Scopus)
16 Downloads (Pure)

Abstract

The development of immune checkpoint inhibitors (ICIs) has a tremendous effect on the treatment options for multiple types of cancer. Nonetheless, there is a large interpatient variability in response, survival, and the development of immune-related adverse events (irAEs). Pharmacogenetics is the general term for germline genetic variations, which may cause the observed interindividual differences in response or toxicity to treatment. These genetic variations can either be single-nucleotide polymorphisms (SNPs) or structural variants, such as gene deletions, amplifications or rearrangements. For ICIs, pharmacogenetic variation in the human leukocyte antigen molecules has also been studied with regard to treatment outcome. This review presents a summary of the literature regarding the pharmacogenetics of ICI treatment, discusses the most important known genetic variations and offers recommendations on the application of pharmacogenetics for ICI treatment.

Original languageEnglish
Article number102662
JournalCancer Treatment Reviews
Volume122
DOIs
Publication statusPublished - Jan 2024

Bibliographical note

Publisher Copyright:
© 2023 The Author(s)

Fingerprint

Dive into the research topics of 'Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors'. Together they form a unique fingerprint.

Cite this